Report The Panel agreed on the outline of the 2027 IPCC Methodology Report on Carbon Dioxide Removal Technologies, Carbon Capture, Utilization, and Storage for National Greenhouse Gas Inventories (Additional guidance) at its 63rd Session held in Lima, Peru from 27-30 October 2025 (Decision IPCC-LXIII-6). The report will be a single Methodology Report comprising an Overview Chapter and six volumes consistent with the format of the 2006 IPCC Guidelines for National Greenhouse Gas Inventories. The structure of the Methodology Report is consistent with the 2006 IPCC Guidelines so as to make it easier for inventory compilers to use this Methodology Report with the 2006 IPCC Guidelines. Topics that will be addressed include: Transport, injection and sequestering of CO2 in relation to enhanced oil, gas, and coal-bed methane recovery Production of products containing or derived from captured and/or removed CO2 Carbonation of cement and lime-based structures Soil carbon sinks and related emissions enhanced through biochar and weathering and other elements Coastal wetlands carbon dioxide removal types not in previous IPCC Guidelines as well as additional information on mangroves, tidal marshes and seagrass in coastal waters Durable biomass products Carbon dioxide capture from combustion and process gases Direct air capture Carbon dioxide utilisation Carbon dioxide transport including cross border issues Carbon dioxide injection and storage CO2 removal through direct capture of CO2 from water already processed by inland and coastal facilities; and related elements across the range of categories of the IPCC Guidelines. The national greenhouse gas inventory includes sources and sinks occurring within the territory over which a country has jurisdiction. Over 150 experts are expected to participate in the writing process, which will be completed by 2027. The participants will be selected by the Task Force Bureau taking into account scientific and technical expertise, geographical and gender balance to the extent possible in line with Appendix A to the Principles Governing IPCC Work. The First Lead Authors’ meeting will be held in Rome, Italy, in April 2026. Preparatory Work The decision by the Panel to prepare this Methodology Report was informed by the work of experts at the scoping meeting held in Copenhagen, Denmark, from 14-16 October 2024. Prior to the scoping meeting, an expert meeting was held at Vienna, Austria 1-3 July 2024. These meetings considered Carbon Dioxide Removal (CDR) methods mentioned in the AR6 WGIII Report as a starting point for discussion and noted that several CDR activities have been already covered by the existing IPCC Guidelines. More Information The IPCC Secretary has written to national government focal points inviting nominations of authors by 12 December 2025.

Fast Facts Medicaid programs that cover prescription drugs are generally required to cover drugs that are (1) FDA approved and (2) made by a manufacturer that participates in the Medicaid Drug Rebate Program. 13 Medicaid programs didn’t cover Mifeprex and its generic equivalent, Mifepristone Tablets, 200 mg, when required. These drugs are used for medical abortion. We recommended the Centers for Medicare & Medicaid Services ensure Medicaid programs comply with federal requirements for covering Mifepristone Tablets, 200 mg. We also reiterated our 2019 recommendation on Mifeprex, which hasn’t been implemented. White pills spilling from a pill bottle. Skip to Highlights Highlights What GAO Found Medicaid programs that choose to cover outpatient prescription drugs are required to cover all Food and Drug Administration (FDA) approved drugs for their medically accepted indications when those drugs are made by a manufacturer that participates in the Medicaid Drug Rebate Program (MDRP), except as outlined in federal law. The FDA has approved two drugs—Mifeprex in 2000 and its generic equivalent in 2019, referred to as Mifepristone Tablets, 200 mg—for the medical termination of an intrauterine pregnancy, known as a medical abortion. Danco Laboratories and GenBioPro are the exclusive manufacturers of Mifeprex and Mifepristone Tablets, 200 mg, respectively, and both manufacturers participate in the MDRP. Medicaid programs in all 50 states, the District of Columbia, and Puerto Rico cover prescription drugs and participate in the MDRP. According to officials from the Centers for Medicare & Medicaid Services (CMS)—the federal agency within the Department of Health and Human Services (HHS) responsible for ensuring Medicaid programs’ compliance—none of the MDRP’s statutory exceptions apply to Mifeprex or Mifepristone Tablets, 200 mg. Thus, these 52 Medicaid programs must cover these drugs when prescribed for medical abortion in circumstances eligible for federal funding, such as when the pregnancy is the result of rape or incest. GAO identified gaps in Medicaid programs’ coverage of Mifeprex and Mifepristone Tablets, 200 mg. Officials from 35 of the 49 programs who responded to GAO questions said their programs covered Mifeprex and Mifepristone Tablets, 200 mg for medical abortion, as of December 31, 2024. In contrast, officials from 13 programs told GAO their programs did not cover either drug for medical abortion. An official from the remaining program did not specify the medical indications for which its program covered the drugs. Medicaid Programs’ Coverage of Danco Laboratories’ Mifeprex and GenBioPro’s Mifepristone Tablets, 200 mg, as of December 31, 2024 Note: For more details, see fig. 1 in GAO-25-107911. State officials’ responses to GAO’s questions indicated that some states may not be complying with the MDRP requirements for covering Mifeprex and Mifepristone Tablets, 200 mg. However, CMS has not determined the extent to which states comply with the MDRP requirements for these drugs. CMS officials told GAO they were not aware of the following: Nine programs did not cover Mifeprex and Mifepristone Tablets, 200 mg for any medical indication, as of December 31, 2024; GAO reported four of these programs did not cover Mifeprex in 2019. Mifepristone Tablets, 200 mg was not available at the time of GAO’s 2019 report. Four additional Medicaid programs did not cover either drug when prescribed for medical abortion, as of December 31, 2024. CMS was not aware of these coverage gaps, in part, because it had not implemented GAO’s 2019 recommendation to take actions to ensure Medicaid programs comply with MDRP requirements to cover Mifeprex. CMS also has not taken actions related to the coverage of Mifepristone Tablets, 200 mg, as of August 2025. Without such actions, CMS lacks assurance that Medicaid programs comply with MDRP requirements and Medicaid beneficiaries may lack access to these drugs when appropriate. Why GAO Did This Study GAO was asked to describe Medicaid programs’ coverage of mifepristone. This report examines Medicaid programs’ coverage of Mifeprex and Mifepristone Tablets, 200 mg, among other things. GAO reviewed laws and CMS guidance on the MDRP, and coverage of Mifeprex and Mifepristone Tablets, 200 mg. GAO also sent written questions to officials from the 52 Medicaid programs that participate in the MDRP regarding their coverage of these drugs, and reviewed officials’ responses from the 49 programs that provided GAO information. Recommendations GAO reiterates its 2019 recommendation that CMS take actions to ensure states’ compliance with MDRP requirements to cover Mifeprex. GAO also recommends that CMS determine the extent to which states comply with federal Medicaid requirements regarding coverage of GenBioPro’s Mifepristone Tablets, 200 mg, and take actions, as appropriate, to ensure compliance. In response to the recommendation, HHS noted it is reviewing applicable law and will determine the best course of action to address it moving forward. Recommendations for Executive Action Agency Affected Recommendation Status Centers for Medicare & Medicaid Services The Administrator of CMS should determine the extent to which states comply with federal Medicaid requirements regarding coverage of GenBioPro's Mifepristone Tablets, 200 mg, and take actions, as appropriate, to ensure compliance. (Recommendation 1) Open Actions to satisfy the intent of the recommendation have not been taken or are being planned. When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information. Full Report Full Report (11 pages)

05.12.2025 – The European Scientific Advisory Board on Climate Change, established under the European Climate Law, will continue to be supported in its second term (2026-2030) by Ottmar Edenhofer. The Director of the Potsdam Institute for Climate Impact Research (PIK) has now been appointed by the Management Board of the European Environment Agency in Copenhagen for another four-year term on the Advisory Board, beginning on 24 March 2026. Advising EU policymakers on the path to the declared goal of climate neutrality: PIK Director Ottmar Edenhofer. Photo: PIK/Karkow The Advisory Board gives independent advice and produces reports on EU policies, and their coherence with the Climate Law and the EU’s commitments under the Paris Agreement. It consists of 15 high-level scientific experts covering a wide range of relevant fields. Edenhofer is serving as the Advisory Board’s current Chair during its first term (2022-2026). Highlights during this period have included scientific recommendations for an ambitious EU climate target for 2040, an analysis of the action needed to achieve climate neutrality, and a study on scaling up atmospheric carbon removals. “I am very thankful for the great opportunity to continue supporting EU climate policy in this service role for the next four years,” says Edenhofer, who is also Professor for The Economics and Politics of Climate Change at the Technische Universität Berlin. “The European Union has taken some important steps in recent years towards its declared goal of climate neutrality by 2050. It remains important to make climate policy cost-effective, socially balanced and consistent with the requirements of an internationally competitive economy. As a member of the Advisory Board, I will do my best to provide scientific advice to policymakers on this task.” The composition of the Advisory Board for the next four-year term has now been decided through an open, fair and transparent selection process lasting several months. The decision on who will chair the body in future is not expected until beginning of the second term. The other members of the Advisory Board in the second term are: • Annela Anger-Kraavi – University of Cambridge • Constantinos Cartalis – National and Kapodistrian University of Athens • Suraje Dessai – University of Leeds’ School of Earth, Environment, and Sustainability • Laura Díaz Anadón – University of Cambridge • Vera Eory – Scotland’s Rural College • Lena Kitzing - Technical University of Denmark • Kati Kulovesi – University of Eastern Finland • Lars J. Nilsson – Lund University • Åsa Persson – KTH Royal Institute of Technology’s Climate Action Centre • Keywan Riahi – International Institute for Applied Systems Analysis • Jean-François Soussana – French National Research Institute for Agriculture, Food and the Environment • Giorgio Vacchiano – University of Milan • Detlef van Vuuren – PBL Netherlands Environmental Assessment Agency • Zinta Zommers – University of Toronto

Abstract Sulfur hexafluoride (SF6) is a persistent, highly potent greenhouse gas that is accumulating in the atmosphere at an increasing rate, exacerbating climate change. Whereas current degradation methods rely on forcing conditions to dissociate the inert molecule and additionally require post-treatment with basic solution to obtain harmless products, we show that SF6 is mineralized in a single step at ambient temperature using potassium hydroxide in water/isopropyl alcohol mixtures under UV irradiation. The reaction proceeds via an autocatalytic mechanism, where in situ-generated acetone acts as a photosensitizer, leading to the selective formation of potassium sulfite and fluoride salts. Compared to existing methods, this approach eliminates the need for extreme temperatures, hazardous catalysts, or post-treatment, providing a scalable and easy-to-apply strategy for SF6 degradation.

Abstract Metal halide perovskite quantum dots (PQDs), particularly formamidinium lead triiodide (FAPbI3) PQDs, have garnered significant attention for high-efficiency solar cells due to their ideal optical properties and stable phase structure. However, achieving desired colloidal dispersion and charge transport of FAPbI3 PQDs still remains challenging. Herein, we report an efficient in-situ entropic ligand engineering strategy, using bis(2-ethylhexyl) phosphate (DEHP), to achieve improved dispersibility and charge transport in organic-inorganic hybrid FAPbI3 PQDs. The branched 2-ethylhexyl tails of DEHP increase configurational entropy, improving solvent interaction and colloidal stability. In addition, the phosphinic acid head anchoring group of DEHP exhibits stronger binding strength for enhanced surface passivation and reduced core-core interactions. By optimizing the addition of entropic ligand, the DEHP-capped PQDs exhibit high colloidal stability and favorable optical properties, resulting in a power conversion efficiency (PCE) of 18.68% (certified value 18.23%) for PQD solar cells, along with improved stability. We believe these findings would provide insights to the design and synthesis of metal halide PQDs to construct desired films for optoelectronic applications.

Abstract Integrin-mediated cell adhesion and mechanotransduction are considered key innovations in animal evolution. Here, we show that these processes represent a specialization of an evolutionarily conserved force coupling mechanism that originated in unicellular organisms and is mediated by the actin-binding protein talin. In contrast to heterodimeric integrin receptors, talin is widely distributed in unicellular organisms, including amoebae. By comparing the molecular mechanics of talin-A from amoeboid cells with that of mammalian talin-1, we uncover a conserved role for talin in transmitting pN-scale forces, even in unicellular organisms lacking canonical integrin receptors but expressing the functional homologue SibA. Our data indicate that the critical evolutionary steps towards integrin-mediated cell adhesion in metazoan organisms were the specialization of talin as an adaptor protein allowing the activation of integrin receptors, the regulation of biochemical signaling by paxillin, FAK and YAP, and the control of cell adhesion turnover by KANK recruitment. Collectively, these experiments suggest a central but thus far underappreciated role for talin in the evolution of eukaryotic cell-substrate adhesion and force transmission.

Abstract Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to its aggressive nature and limited treatment options, with the efficacy of immunotherapy constrained by a uniquely immunosuppressive tumor microenvironment (TME). In this study, we identify TNK2/ACK1 as a key regulator of the immunosuppressive TME in PDAC. TNK2/ACK1 is significantly upregulated in PDAC, at least in part via gene amplification and KRAS-G12 mutations. Mechanistically, TNK2/ACK1 directly phosphorylates and activates STAT5A to induce the expression of the immune checkpoint HVEM, which suppresses CD8⁺ T-cell function via its receptor BTLA. Pharmacologic targeting of TNK2/ACK1 with AIM100 or (R)−9b enhances CD8⁺ T-cell activation and cytotoxicity while reprogramming the TME. Furthermore, combining TNK2/ACK1 inhibitors with anti-PD-1 immunotherapy or with nab-paclitaxel plus gemcitabine demonstrates promising antitumor efficacy in both allograft and spontaneous PDAC models. Overall, our findings reveal a mechanism of immune evasion and provide a potential framework for developing tailored immunotherapeutic strategies in PDAC.